AC Immune SA (ACIU), a clinical-stage Swiss biopharmaceutical company developing precision therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's, trades near $2.25 a share. A $9 price level would represent a roughly 300% move from current levels, making the question one of pipeline execution and investor re-rating rather than near-term earnings.
Three current, attributable analyst price targets were identified for this analysis. Andrew Fein of H.C. Wainwright reiterated a Buy with a $12.00 target in September 2026; Thomas Shrader of BTIG reiterated a Buy with an $8.00 target in September 2026; and Jefferies maintained a Buy with a $7.00 target in March 2026. The arithmetic mean of these three figures is $9.00, which serves as the central target here, with an approximate range of $7.00 to $12.00.
Notably, this range is wide — the highest target is roughly 70% above the lowest — reflecting genuine disagreement about how much of AC Immune's pipeline value will be realized. Third-party consensus figures vary (some providers report averages near $7.50 to $8.60) because they include different analysts; the $9 figure is this analysis's own calculation from attributable targets, not an official published consensus. H.C. Wainwright's Buy rests on Phase 2 ACI-7104 data validating the platform, while BTIG's valuation leans on a discounted-cash-flow view of a diversified neuroscience pipeline and cash runway into late 2027.
With the latest price near $2.25, moving to $9.00 implies upside of approximately 300% — a very large move that would require the stock to nearly quadruple. The shares sit toward the lower end of a 52-week range of roughly $2.03 to $4.00 and below their 50-day and 200-day moving averages, indicating the market has been discounting the company's fundamentals despite upbeat clinical news.
A path toward $9 would likely require successive, de-risking clinical readouts rather than any single catalyst. AC Immune reported second-quarter revenue of about $18.67 million versus roughly $9.59 million expected, and a modest EPS (earnings per share) beat, but the company remains unprofitable with a negative net margin. Reaching the target would depend on continued progression of programs such as ACI-7104 in Parkinson's, ACI-24 for Alzheimer's, and the ACI-19764 NLRP3 inhibitor, alongside partner milestones from collaborators including Genentech (Roche), Janssen, and Eli Lilly.
Positive interim Phase 2 data for ACI-7104 in early Parkinson's disease — meeting primary endpoints with strong immunogenicity and improved CNS (central nervous system) exposure — has been cited by analysts as validating the company's SupraAntigen platform. The company's cash position of roughly $75 million and a runway extending into late 2027 reduce near-term financing risk. Multiple collaborations with large pharmaceutical partners provide non-dilutive funding and external validation, while a diversified pipeline across Alzheimer's, Parkinson's, and neuroinflammation offers several potential value inflection points.
Clinical-stage biotech carries binary risk: a failed or ambiguous trial in any lead program could sharply compress the valuation. The company continues to post net losses and negative free cash flow, leaving it dependent on partners and future capital raises that could dilute shareholders. The wide analyst target range itself signals uncertainty, and the stock's persistent discount to every published target — including a 52-week high of only $4.00 — reflects skepticism that the pipeline will convert into approved products. Small sample sizes and exploratory endpoints in recent readouts add further caution.
The shares have carved a durable trading band between the 52-week low near $2.03 and the 52-week high near $4.00. The $4.00 area stands as the most meaningful resistance level, and the $2.00–$2.10 zone represents key support. The stock currently trades below its 50-day and 200-day moving averages, indicating a weak longer-term trend structure; a sustained move above $4.00 would be a notable structural signal on any path toward the $9 target.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may apply different frameworks. Investors should watch the next earnings report, clinical data updates for ACI-7104 and ACI-24, the ACI-19764 Phase 1 results, and any partner milestone or licensing news. Analyst target revisions — particularly any changes from H.C. Wainwright, BTIG, or Jefferies — and financing activity are also worth monitoring closely.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like ACIU, these signals can help traders spot shifting trends more efficiently than manual chart review. The tool is designed to surface opportunities, support position monitoring, and flag momentum changes. Traders seeking a data-driven edge may find it a useful complement to their own research.
Can AC Immune (ACIU) reach $9? The target reflects the mean of three attributable analyst objectives ($7, $8, and $12) and would require a roughly 300% advance from the current price near $2.25 — a very large move that is not supported by the stock's recent trading range. The bull case rests on platform validation from positive Parkinson's Phase 2 data and a funded runway into late 2027, while the bear case centers on binary clinical risk, ongoing losses, and a market that has persistently valued the shares far below analyst targets. The wide target spread underscores genuine uncertainty. Investors should weigh upcoming clinical readouts and partner developments rather than treat any single price objective as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ACIU has been loosely correlated with SANA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ACIU jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To ACIU | 1D Price Change % | ||
|---|---|---|---|---|
| ACIU | 100% | -0.47% | ||
| SANA - ACIU | 43% Loosely correlated | +0.50% | ||
| EDIT - ACIU | 42% Loosely correlated | +1.40% | ||
| KYTX - ACIU | 42% Loosely correlated | +0.40% | ||
| ALEC - ACIU | 41% Loosely correlated | +3.67% | ||
| BEAM - ACIU | 41% Loosely correlated | -4.99% | ||
More | ||||